Outcome of the Board Meeting held on 13th November, 2025 for approval of un-audited result as on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Chandra Bhagat Pharma's H1 FY26 (Apr–Sep 2025) revenue came in at ₹25.55 crore, a sharp ~60% decline from ₹64.92 crore in H1 FY25. Despite the steep fall in top line, the company remained profitable with profit before tax of ₹58.62 lakhs (vs ₹61.25 lakhs) and profit after tax of ₹44.91 lakhs (vs ₹68.49 lakhs, a ~34% drop). EBITDA-style margins expanded meaningfully as cost of materials and other expenses were scaled down faster than revenue. Operating cash flow turned around from a ₹728.10 lakh outflow last year to a ₹96.81 lakh inflow this year, helped by better collections and lower payables. Statutory auditor A Y & Company issued a clean (unqualified) limited review report; no exceptional items, auditor changes, or investor complaints were reported.
The steep revenue slump is a red flag, but strict cost control, expanding margins, and a return to positive operating cash flow cushion the picture. Stock reaction will likely hinge on whether revenue stabilises in the second half of FY26.